A$145.97
Chart
Performance
Key Stats
AI A Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyAgilent Technologies presents a compelling investment case, supported by strong fundamentals in the life sciences and diagnostics sectors. While short-term technical indicators suggest some caution, the company's consistent earnings, healthy balance sheet, and promising growth prospects in key markets position it favorably for long-term investors.
Thematic
Agilent is well-positioned within the life sciences, diagnostics, and applied chemical markets, benefiting from secular growth trends like increased healthcare spending, advancements in genomics, and demand for analytical instrumentation. Emerging areas like personalized medicine and biopharmaceutical development provide further tailwinds.
Fundamental
Agilent demonstrates robust financial health with consistent profitability, a strong balance sheet, and positive free cash flow generation. Its valuation metrics, while not exceptionally cheap, are reasonable given its market position and growth prospects.
Technical
Agilent's stock shows a positive long-term trend, trading above key moving averages. However, recent performance has been mixed, and current technical indicators suggest a period of consolidation or minor price fluctuations.
| Factor | Score |
|---|---|
| Life Sciences & Healthcare Demand | 85 |
| Genomics & Precision Medicine | 75 |
| Applied Chemical Markets | 65 |
| Technological Advancements | 70 |
| Regulatory Environment | 70 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 85 |
| Growth | 70 |
| Balance Sheet Health | 80 |
| Cash Flow | 85 |
| Dividend Yield | 60 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 65 |
| Volume Confirmation | 70 |
| Support & Resistance | 70 |
| Short-term Oscillators | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent EPS Beat
The company has consistently surpassed EPS estimates for the last 12 quarters, with an average surprise of +5.1%, indicating strong operational execution and forecasting accuracy.
Undervalued Growth Potential
The Price-to-Earnings (P/E) ratio of 29.64 is below the industry average of 35.5, suggesting potential undervaluation relative to its growth prospects, especially given its forward P/E of 25.1.
Bearish Points (7)
Elevated P/S Ratio
The trailing Price-to-Sales (P/S) ratio of 5.17, while down from its peak, remains higher than the 5-year average of 4.8, suggesting that high sales growth expectations are priced in.
Slowing Revenue Growth
While profitable, annual revenue growth has shown a slight deceleration from 19.1% in 2021 to 18.3% in 2022 and 18.1% in 2023, signaling a potential slowdown in expansion.
Calendar
July 2025
1
Ex-Dividend Date
July 2025
23
Next Dividend Date
August 2025
28
Next Earnings Date
H: $1.39
A: $1.37
L: $1.36
H: 1.68B
A: 1.67B
L: 1.66B
Profile
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. This segment also offers GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies. The Diagnostics and Genomics segment provides genomics, contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses; and cell analysis plate based assays, flow cytometers, real-time cell analyzers, cell imaging systems, microplate readers, and related consumables. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Seasonals
Price Target
136.82 USD
The 39 analysts offering 1 year price forecasts for A have a max estimate of 165.00 and a min estimate of 113.20.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Exclusive manufacturer of Apple's custom A-series and M-series chips, which are crucial for the performance of iPhones, iPads, and Mac computers.
Weight: 95
Primary assembler of iPhones, iPads, and other major Apple products globally, making it a critical and irreplaceable part of Apple's supply chain.
Weight: 90
Key supplier of cellular modem chips for iPhones and iPads, and a historical partner with whom Apple has also engaged in significant patent disputes.
Weight: 88
Major supplier of Wi-Fi, Bluetooth, and other radio-frequency components essential for wireless connectivity in Apple's devices.